Shareholder Alert: Ademi LLP investigates whether Peak Bio Inc. has obtained a Fair Price in its transaction with Akari

MILWAUKEE, March 5, 2024 /PRNewswire/ -- Ademi LLP is investigating Peak Bio (OTC: PKBO) for possible breaches of fiduciary duty and other violations of law in its transaction with Akari.

Click here to learn how to join the https://www.ademilaw.com/case/peak-bio-inc or call Guri Ademi toll-free at 866-264-3995. There is no cost or obligation to you.

In the transaction, Peak Bio shareholders will receive only Peak Bio stockholders will receive a number of Akari ordinary shares (represented by American Depositary Shares) for each share of Peak stock they own, as determined on the basis of the exchange ratio described in the agreement. The transaction agreement unreasonably limits competing transactions for Peak Bio by imposing a significant penalty if Peak Bio accepts a competing bid. Peak Bio insiders will receive substantial benefits as part of change of control arrangements.

We are investigating the conduct of Peak Bio's board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.

If you own Peak Bio common stock and wish to obtain additional information, please contact Guri Ademi either at [email protected] or toll-free: 866-264-3995, or https://www.ademilaw.com/case/peak-bio-inc.  

We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights throughout the country. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.

Contacts

Ademi LLP
Guri Ademi
Toll Free: (866) 264-3995
Fax: (414) 482-8001

SOURCE Ademi LLP